NL9401534A - Gebruik van zetmeel voor parenterale toepassingen. - Google Patents
Gebruik van zetmeel voor parenterale toepassingen. Download PDFInfo
- Publication number
- NL9401534A NL9401534A NL9401534A NL9401534A NL9401534A NL 9401534 A NL9401534 A NL 9401534A NL 9401534 A NL9401534 A NL 9401534A NL 9401534 A NL9401534 A NL 9401534A NL 9401534 A NL9401534 A NL 9401534A
- Authority
- NL
- Netherlands
- Prior art keywords
- implant
- filling
- starch
- active substance
- formulation
- Prior art date
Links
- 229920002472 Starch Polymers 0.000 title claims abstract description 64
- 239000008107 starch Substances 0.000 title claims abstract description 64
- 235000019698 starch Nutrition 0.000 title claims abstract description 64
- 239000007943 implant Substances 0.000 claims abstract description 63
- 241001465754 Metazoa Species 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 13
- 239000002245 particle Substances 0.000 claims abstract description 13
- 239000007787 solid Substances 0.000 claims abstract description 12
- 239000000203 mixture Substances 0.000 claims description 20
- 239000013543 active substance Substances 0.000 claims description 19
- 238000011049 filling Methods 0.000 claims description 16
- 239000000427 antigen Substances 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 13
- 239000000839 emulsion Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 239000011247 coating layer Substances 0.000 claims description 7
- 239000010410 layer Substances 0.000 claims description 6
- 229920001577 copolymer Polymers 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000004626 polylactic acid Substances 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 230000036760 body temperature Effects 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 239000004633 polyglycolic acid Substances 0.000 claims description 3
- 230000002745 absorbent Effects 0.000 claims description 2
- 239000002250 absorbent Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000007710 freezing Methods 0.000 claims 2
- 230000008014 freezing Effects 0.000 claims 2
- 239000012531 culture fluid Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 description 29
- 239000007924 injection Substances 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 20
- 239000000284 extract Substances 0.000 description 20
- 230000000694 effects Effects 0.000 description 17
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 102000013142 Amylases Human genes 0.000 description 12
- 108010065511 Amylases Proteins 0.000 description 12
- 235000019418 amylase Nutrition 0.000 description 10
- 238000002513 implantation Methods 0.000 description 10
- 239000004382 Amylase Substances 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000003111 delayed effect Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 238000001746 injection moulding Methods 0.000 description 6
- 210000003205 muscle Anatomy 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
- 229920000856 Amylose Polymers 0.000 description 5
- 206010020751 Hypersensitivity Diseases 0.000 description 5
- 206010042674 Swelling Diseases 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 235000012343 cottonseed oil Nutrition 0.000 description 5
- 239000002385 cottonseed oil Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000002054 inoculum Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000033687 granuloma formation Effects 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 229920000945 Amylopectin Polymers 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 230000002308 calcification Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 238000013334 tissue model Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 241001672694 Citrus reticulata Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940025131 amylases Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229920000704 biodegradable plastic Polymers 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002327 eosinophilic effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001235 gentian violet Drugs 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100001228 moderately toxic Toxicity 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 231100000925 very toxic Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9401534A NL9401534A (nl) | 1994-09-21 | 1994-09-21 | Gebruik van zetmeel voor parenterale toepassingen. |
| EP02076359A EP1250936A1 (de) | 1994-09-21 | 1995-09-20 | Verwendung von Stärke in transdermalen Anwendungen |
| DE69529991T DE69529991T2 (de) | 1994-09-21 | 1995-09-20 | Verwendung von stärke zu kinetischer transdermaler anwendung |
| AT95933647T ATE234633T1 (de) | 1994-09-21 | 1995-09-20 | Verwendung von stärke zu kinetischer transdermaler anwendung |
| EP95933647A EP0774975B1 (de) | 1994-09-21 | 1995-09-20 | Verwendung von stärke zu kinetischer transdermaler anwendung |
| US08/809,096 US6001385A (en) | 1994-09-21 | 1995-09-20 | Use of starch for transdermal applications |
| PCT/NL1995/000313 WO1996009070A1 (en) | 1994-09-21 | 1995-09-20 | Use of starch for transdermal applications |
| DK95933647T DK0774975T3 (da) | 1994-09-21 | 1995-09-20 | Brug af stivelse til kinetiske transdermale anvendelser |
| AU36200/95A AU711798B2 (en) | 1994-09-21 | 1995-09-20 | Use of starch for transdermal applications |
| ES95933647T ES2194056T3 (es) | 1994-09-21 | 1995-09-20 | Uso de almidon para aplicaciones cineticas transdermicas. |
| JP8510770A JPH10505858A (ja) | 1994-09-21 | 1995-09-20 | 経皮施用へのスターチ使用 |
| PT95933647T PT774975E (pt) | 1994-09-21 | 1995-09-20 | Utilizacao de amido para aplicacoes transdermicas cineticas |
| NZ293695A NZ293695A (en) | 1994-09-21 | 1995-09-20 | A transdermal implant containing fully destructurized starch |
| CA002200595A CA2200595C (en) | 1994-09-21 | 1995-09-20 | Use of starch for transdermal applications |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9401534 | 1994-09-21 | ||
| NL9401534A NL9401534A (nl) | 1994-09-21 | 1994-09-21 | Gebruik van zetmeel voor parenterale toepassingen. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL9401534A true NL9401534A (nl) | 1996-05-01 |
Family
ID=19864679
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL9401534A NL9401534A (nl) | 1994-09-21 | 1994-09-21 | Gebruik van zetmeel voor parenterale toepassingen. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US6001385A (de) |
| EP (2) | EP1250936A1 (de) |
| JP (1) | JPH10505858A (de) |
| AT (1) | ATE234633T1 (de) |
| AU (1) | AU711798B2 (de) |
| CA (1) | CA2200595C (de) |
| DE (1) | DE69529991T2 (de) |
| DK (1) | DK0774975T3 (de) |
| ES (1) | ES2194056T3 (de) |
| NL (1) | NL9401534A (de) |
| NZ (1) | NZ293695A (de) |
| PT (1) | PT774975E (de) |
| WO (1) | WO1996009070A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0992251A1 (de) * | 1998-10-07 | 2000-04-12 | Isotis B.V. | Vorrichtung zur Knochenbehandlung eines Knochersatzmaterials |
| GB2391480B (en) | 2002-08-05 | 2007-02-28 | Caretek Medical Ltd | Drug delivery system |
| US7615234B2 (en) * | 2001-09-11 | 2009-11-10 | Glide Pharmaceutical Technologies Limited | Drug delivery technology |
| GB2379390B (en) * | 2001-09-11 | 2005-01-26 | Caretek Medical Ltd | A novel drug delivery technology |
| US20030159612A1 (en) * | 2002-02-28 | 2003-08-28 | Terrance Ziemack | Ballistic implant system and methods |
| EP1354512A1 (de) * | 2002-04-19 | 2003-10-22 | Coöperatieve Verkoop- en Productievereniging van Aardappelmeel en Derivaten 'AVEBE' B.A. | Kauprodukt für Haustiere |
| US20040202632A1 (en) * | 2003-04-10 | 2004-10-14 | Unilever Home & Personal Care Usa, Division Of Conocpo, Inc. | Fragranced solid cosmetic compositions based on a starch delivery system |
| US7133638B2 (en) * | 2004-11-18 | 2006-11-07 | Xerox Corporation | Scanning method and an image-processing device including the same |
| GB2422784A (en) * | 2005-02-07 | 2006-08-09 | Caretek Medical Ltd | Disposable assembly comprising a needle or stylet |
| US9615851B2 (en) | 2005-11-11 | 2017-04-11 | Waveform Technologies, Inc. | Method and apparatus for insertion of a sensor |
| US20070173706A1 (en) * | 2005-11-11 | 2007-07-26 | Isense Corporation | Method and apparatus for insertion of a sensor |
| US7294350B2 (en) * | 2006-03-21 | 2007-11-13 | Marraccini Philip A | Healing powder and method of use thereof |
| AU2007314150B2 (en) * | 2006-11-01 | 2009-06-04 | Smartvet Pty Ltd | Delivery system for remote treatment of an animal |
| GB2446780A (en) | 2007-02-22 | 2008-08-27 | Glide Pharmaceutical Technolog | An elongate parenteral injection body having an injection point of angle 10 to 40 degrees. |
| WO2008105663A1 (en) * | 2007-03-01 | 2008-09-04 | Bioneedle Technologies Group B.V. | Implant containing destructurized starch |
| EP2115008B1 (de) * | 2007-03-01 | 2019-09-18 | De Staat der Nederlanden, vert. door de Minister van Volksgezondheid, Welzijn en Sport, namens de Minister, Projectdirectie ALT, het INTRAVACC | Auf offener stärke basierendes, biologisch abbaubares material |
| US8551505B2 (en) | 2008-10-31 | 2013-10-08 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8725420B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9060934B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8788211B2 (en) | 2008-10-31 | 2014-07-22 | The Invention Science Fund I, Llc | Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition |
| US9050317B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8731840B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US9050070B2 (en) | 2008-10-31 | 2015-06-09 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US8731841B2 (en) | 2008-10-31 | 2014-05-20 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8721583B2 (en) | 2008-10-31 | 2014-05-13 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9072799B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9072688B2 (en) | 2008-10-31 | 2015-07-07 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8793075B2 (en) | 2008-10-31 | 2014-07-29 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US8409376B2 (en) | 2008-10-31 | 2013-04-02 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US9060926B2 (en) | 2008-10-31 | 2015-06-23 | The Invention Science Fund I, Llc | Compositions and methods for therapeutic delivery with frozen particles |
| US20100111857A1 (en) | 2008-10-31 | 2010-05-06 | Boyden Edward S | Compositions and methods for surface abrasion with frozen particles |
| US8762067B2 (en) | 2008-10-31 | 2014-06-24 | The Invention Science Fund I, Llc | Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data |
| US8545855B2 (en) | 2008-10-31 | 2013-10-01 | The Invention Science Fund I, Llc | Compositions and methods for surface abrasion with frozen particles |
| US10376213B2 (en) | 2009-06-30 | 2019-08-13 | Waveform Technologies, Inc. | System, method and apparatus for sensor insertion |
| ES2362525B8 (es) | 2009-10-08 | 2013-01-03 | Azurebio, S.L. | Formulación de medicamentos en forma de agujas percutaneas penetrantes. |
| US8875658B2 (en) | 2011-11-30 | 2014-11-04 | A.J. Boggs & Company | Projectile pet food |
| GB201317641D0 (en) | 2013-10-05 | 2013-11-20 | Chowdhury Dewan F H | Novel solid dosage form |
| EP4499051A1 (de) | 2022-03-30 | 2025-02-05 | Bioneedle Drug Delivery B.V. | Verfahren zur lagerung biologisch aktiver konstrukte in einem biologisch abbaubaren material |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE645215A (de) * | 1964-03-13 | 1964-07-01 | ||
| DE3521893A1 (de) * | 1984-06-19 | 1985-12-19 | Československá akademie věd, Prag/Praha | Biologisch abbaubares implantat mit cytostatischer wirkung und seine herstellung |
| WO1987006129A1 (en) * | 1986-04-10 | 1987-10-22 | Daratech Pty. Ltd. | Vaccine and implant |
| WO1992015285A1 (en) * | 1991-03-01 | 1992-09-17 | Warner-Lambert Company | Starch-based controlled release compositions |
| WO1993023012A1 (en) * | 1992-05-14 | 1993-11-25 | Endocon, Inc. | Liquid-containing drug delivery system |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616758A (en) * | 1968-10-24 | 1971-11-02 | Vladil Afanasievich Komarov | Shell for the immobilization of animals |
| US4673438A (en) * | 1984-02-13 | 1987-06-16 | Warner-Lambert Company | Polymer composition for injection molding |
| GB2206888B (en) * | 1987-07-07 | 1991-02-06 | Warner Lambert Co | A destructurized starch and a process for making same |
-
1994
- 1994-09-21 NL NL9401534A patent/NL9401534A/nl not_active Application Discontinuation
-
1995
- 1995-09-20 ES ES95933647T patent/ES2194056T3/es not_active Expired - Lifetime
- 1995-09-20 WO PCT/NL1995/000313 patent/WO1996009070A1/en not_active Ceased
- 1995-09-20 DK DK95933647T patent/DK0774975T3/da active
- 1995-09-20 DE DE69529991T patent/DE69529991T2/de not_active Expired - Lifetime
- 1995-09-20 EP EP02076359A patent/EP1250936A1/de not_active Withdrawn
- 1995-09-20 PT PT95933647T patent/PT774975E/pt unknown
- 1995-09-20 EP EP95933647A patent/EP0774975B1/de not_active Expired - Lifetime
- 1995-09-20 US US08/809,096 patent/US6001385A/en not_active Expired - Lifetime
- 1995-09-20 CA CA002200595A patent/CA2200595C/en not_active Expired - Fee Related
- 1995-09-20 AU AU36200/95A patent/AU711798B2/en not_active Ceased
- 1995-09-20 NZ NZ293695A patent/NZ293695A/xx not_active IP Right Cessation
- 1995-09-20 AT AT95933647T patent/ATE234633T1/de active
- 1995-09-20 JP JP8510770A patent/JPH10505858A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE645215A (de) * | 1964-03-13 | 1964-07-01 | ||
| DE3521893A1 (de) * | 1984-06-19 | 1985-12-19 | Československá akademie věd, Prag/Praha | Biologisch abbaubares implantat mit cytostatischer wirkung und seine herstellung |
| WO1987006129A1 (en) * | 1986-04-10 | 1987-10-22 | Daratech Pty. Ltd. | Vaccine and implant |
| WO1992015285A1 (en) * | 1991-03-01 | 1992-09-17 | Warner-Lambert Company | Starch-based controlled release compositions |
| WO1993023012A1 (en) * | 1992-05-14 | 1993-11-25 | Endocon, Inc. | Liquid-containing drug delivery system |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0774975T3 (da) | 2003-07-14 |
| JPH10505858A (ja) | 1998-06-09 |
| EP1250936A1 (de) | 2002-10-23 |
| AU711798B2 (en) | 1999-10-21 |
| PT774975E (pt) | 2003-08-29 |
| US6001385A (en) | 1999-12-14 |
| EP0774975A1 (de) | 1997-05-28 |
| DE69529991T2 (de) | 2003-12-11 |
| NZ293695A (en) | 1999-05-28 |
| ATE234633T1 (de) | 2003-04-15 |
| DE69529991D1 (de) | 2003-04-24 |
| ES2194056T3 (es) | 2003-11-16 |
| CA2200595A1 (en) | 1996-03-28 |
| CA2200595C (en) | 2008-06-10 |
| EP0774975B1 (de) | 2003-03-19 |
| WO1996009070A1 (en) | 1996-03-28 |
| AU3620095A (en) | 1996-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU711798B2 (en) | Use of starch for transdermal applications | |
| US5945115A (en) | Polymeric compositions useful as controlled release implants | |
| US5702716A (en) | Polymeric compositions useful as controlled release implants | |
| US4650665A (en) | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition | |
| CA1311686C (en) | Controlled release bioerodible drug delivery system | |
| US4865846A (en) | Drug delivery system | |
| US4568536A (en) | Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition | |
| JP2977724B2 (ja) | 歯周病処置用複合物質 | |
| JP4599498B2 (ja) | 非ポリマー持続性解離供給システム | |
| US4882150A (en) | Drug delivery system | |
| KR100289471B1 (ko) | 휀타닐계마취제의이식형서방성제제 | |
| AU2011208709B2 (en) | Hydrogel of microspheres | |
| US6488952B1 (en) | Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system | |
| JP2009529538A (ja) | サーチュイン活性化剤を用いる眼処置 | |
| KR19990037138A (ko) | 관절 질환 치료용 관절내 투여제제 | |
| WO1994005257A1 (en) | Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle | |
| WO2003009829A2 (en) | Antiemetic, anti-motion sustained release drug delivery system | |
| Graham et al. | Polymeric inserts and implants for the controlled release of drugs | |
| GB2480295A (en) | Polymeric aqueous composition | |
| JPH10279499A (ja) | 子宮粘膜適用製剤 | |
| EP3435971B1 (de) | Amniotische oder plazentazusammensetzung und ophthalmische vorrichtung als wundauflage bei der verbesserten heilung | |
| JPH11222425A (ja) | 関節疾患治療用関節内投与製剤 | |
| Snežana et al. | Polymeric matrix systems for drug delivery | |
| Srikrishna et al. | Recent advancement in Nano-drug delivery for Topical Wound Healing | |
| CN113855621A (zh) | 一种用于痛风急性发作治疗的聚合物微针及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1B | A search report has been drawn up | ||
| BV | The patent application has lapsed |